Bellerophon Therapeutics – Consensus Indicates Potential 297.3% Upside

Broker Ratings

Bellerophon Therapeutics found using ticker (BLPH) have now 4 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The target price ranges between 35 and 19 calculating the mean target price we have 26.5. With the stocks previous close at 6.67 this indicates there is a potential upside of 297.3%. The day 50 moving average is 7.22 and the 200 day moving average is 10.12. The market cap for the company is $66m. Visit the company website at:

Bellerophon Therapeutics, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its products include INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse that is in Phase 2 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; that has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that is in Phase II dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension, pulmonary hypertension associated with pulmonary edema from high altitude sickness, and COVID-19 patients. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics in January 2014. Bellerophon Therapeutics was founded in 2009 and is headquartered in Warren, New Jersey.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits

Good news travels fast (but only if you make that happen):

Share on twitter
Share on linkedin
Share on facebook
Share on email
Share on reddit

AIM All Share Index